Rune Labs Valuation Estimate
Rune Labs Valuation as of Last Funding Round
Rune Labs Company Overview
Rune Labs is a software and data analytics company that uses technology to provide patients with care and help develop and deliver solutions for life sciences companies. It primarily serves the healthcare industry, particularly in neurodegenerative diseases. The company has partnered with the Coastal Research Institute to measure demyelination in patients with spinal cord stimulators, and it has been granted FDA clearance to collect patient symptom data through measurements made by Apple Watch. Rune Labs has raised $41.26 million over five rounds with investors that include Nexus NeuroTech Ventures, Eclipse Ventures, and Moment Ventures.
Rune Labs Valuation History
Rune Labs Stock Price
The stock price of Rune Labs can be calculated by taking the valuation of the company divided by the number of shares outstanding. Because a private company can issue new shares at any time, we do not know the current number of shares outstanding.
For illustrative purposes, however, assuming Rune Labs has issued 250 million shares, at the estimated UpMarket valuation of $46.28 million, each share of Rune Labs stock would be worth $0.19.
Buy Rune Labs Stock
If you would like to buy shares in Rune Labs, please provide your information in the form at the top of this page and click the button titled “I want to buy this stock.”
One of our investor relations team members will contact you to discuss Rune Labs stock availability. Note: inquiries are non-binding and shares may only be purchased by accredited investors that meet all eligibility criteria.
UpMarket has offered many similar companies as Pre-IPO investments, including Airbnb, SpaceX, ByteDance, Plaid, Kraken, Databricks, and others. UpMarket also often has funds available that invest in a portfolio of companies potentially including, Rune Labs as well.
Rune Labs Management
| Name | Position |
|---|---|
| Brian Pepin | CEO |
| Adin Stein | CTO |
| Chase Babcock | COO |